Statistical Issues in Drug Development Stephen S Senn
Publisher: Wiley-Interscience

Analysis of the drug development enterprise invariably reveals a “pipeline” problem—a disconnection between the substantial resources invested in developing new therapies and the rate at which innovative therapeutic products reach patients. Against Counterfeit Drugs Continues. Lynn Torbeck, Statistical Solutions Lynn D. When handled properly, however, cross-company collaboration can result in a more efficient and profitable use of . The author suggests co-opetition as a future model for collaboration in drug development. Further, their statistical predictability and reproducibility are not high [32]. Statistical Issues in Drug Development. Intelligent Drug Development Applied to Drug Transporters by Gerald Clarke - Drug development is growing up. Thus, these biomarkers are not potent to predict risk at early stages of drug development. This strategy is not as simple as it sounds, and issues, such as confidentiality and ownership, can be challenging. There have been many developments since the first edition of this book and it was high time for a second. Statistical Issues in Drug Development, 2nd edition by Stephen Senn English | 2008 | ISBN: 0470018771 | 524 pages | PDF | 4.50 MB Drug development is the process of finding and producing th.